Feature | July 12, 2013

Patient Receives MitraClip Device to Treat Mitral Regurgitation Symptoms as Part of COAPT Trial

Scripps Clinic is only trial site in San Diego to offer MitraClip device

July 12, 2013 — Virginia Anderer, a Chicago native living in southern California, was the first patient in San Diego and at Scripps Health to receive a MitraClip as part of the clinical outcomes assessment of the MitraClip Percutaneous Therapy for High Surgical Risk Patients (COAPT) trial. The MitraClip device is designed to reduce significant mitral regurgitation by clipping together the leaflets of the mitral valve. 


“Traditionally, there have been no good treatment options available for patients like Mrs. Anderer, who suffer from significant mitral regurgitation and are too high risk for surgery,” said Matthew Price, M.D., who implanted the MitraClip device as principal investigator for COAPT at Scripps Clinic. “Now, using advanced imaging techniques and catheters, we were able to repair Mrs. Anderer’s leaking heart valve without the need for open-heart surgery.”


Mitral regurgitation (MR) is the most common type of heart valve defect, affecting approximately one in 10 people aged 75 years and older. The condition occurs when the leaflets of the mitral valve do not close completely, causing blood to flow backward and leak into the left atrium of the heart during each heartbeat.


To maintain an adequate forward flow of blood throughout the body, the heart compensates by increasing the size of the left ventricle, the main pumping chamber of the heart. This requires the heart to work harder, and may ultimately lead to irregular heartbeats, stroke, heart attack or death. MR may also lead to heart failure, a potentially deadly condition that occurs when the heart is unable to pump sufficiently to distribute blood flow to meet the needs of the body.


In Anderer’s case, she was experiencing significant shortness of breath that was getting progressively worse and having a detrimental effect on her quality of life. She was no longer benefiting from medication, and because of her age and medical history, open-heart surgery was not an option. The retired nurse underwent the procedure on June 14 at Scripps Green Hospital and was discharged two days later.


Manufactured by Abbott, MitraClip therapy is designed to reduce MR and provide clinical and quality-of-life benefits for patients suffering from the debilitating symptoms of significant MR by clipping together a portion of the leaflets of the mitral valve. The device is delivered to the heart through the femoral vein in the leg.


“By reducing MR, the hope is that this therapy may allow the heart to recover from overwork and improve function, potentially halting the progression of heart failure and enabling patients to live a higher-quality life,” said Price.


MitraClip is currently under review by the U.S. Food and Drug Administration (FDA), and is commercially available in approximately 30 countries. The European Society of Cardiology (ESC) 2012 heart failure guidelines and the ESC/European Association for Cardio-Thoracic Surgery 2012 guidelines for the management of valvular heart disease specify the MitraClip device as a treatment option for high surgical risk patients with MR.


For more information: www.scripps.org, www.abbottvascular.com


Related Content

Products | Guidewires| July 28, 2015
The Safari2 Pre-Shaped Guidewire.
Feature | Heart Valve Repair| July 28, 2015
Boston Scientific announced CE Mark and U.S. Food and Drug Administration (FDA) clearance for the Safari2 Pre-Shaped...
Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA
News | Heart Valve Repair| July 22, 2015
Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
GlobalData, TAVR, Edwards, Medtronic, CoreValve Evolut R, Sapien 3

Sapien 3 image courtesy of Edwards Lifesciences

News | Heart Valve Repair| July 21, 2015
The recent U.S. Food and Drug Administration (FDA) approvals of two next-generation transcatheter aortic valve...
ACC, health policy statement, heart team, cardiovascular health
Feature | Cardiovascular Surgery| July 17, 2015
Building teams that include advanced practice providers can help cardiovascular practices meet the challenges of modern...
Biotronik, TAVI device, BIOVALVE trial, Hamburg, Germany
News | Heart Valve Repair| July 14, 2015
Biotronik announced the completion of the BIOVALVE first-in-human trial for its new transcatheter aortic valve. Study...
CardiAQ, Edwards, acquire, acquisition, Fortis, TMVI, mitral valve replacement

CardiAQ Transcatheter Mitral Valve Implantation System image courtesy of CardiAQ Valve Technologies

Feature | Heart Valve Repair| July 13, 2015
Edwards Lifesciences Corp. announced that it has agreed to acquire CardiAQ Valve Technologies Inc., a privately held...
Toshiba, CT-angiography, hybrid OR

Toshiba recently introduced a new line of combined CT and angiography systems, allowing true CT imaging on demand in the interventional lab.

Feature | Interventional Radiology| July 07, 2015 | Dave Fornell
All of the major vendors in the United States introduced new systems and technologies in the past few years to reduce...
CardiAQ Valve Technologies, TMVI, second generation, implantation, Tor Vergata
Feature | Heart Valve Repair| July 01, 2015
CardiAQ Valve Technologies (CardiAQ) announced that its second-generation transcatheter bioprosthetic mitral heart...
REDUCE FMR, Cardiac Dimensions, Carillon Mitral Contour System, FMR
Feature | Heart Valve Repair| June 30, 2015
Cardiac Dimensions announced the first patients have been enrolled in the REDUCE FMR clinical trial. REDUCE FMR is a...
Overlay Init